2025年美国临床肿瘤学会(ASCO)年会于当地时间5月30日至6月3日在芝加哥盛大举行。由上海长征医院肖建如、杨诚教授团队开展的“卡瑞利珠单抗联合阿帕替尼治疗难治性脊索瘤的单臂II期临床研究”结果以口头报告的形式亮相大会现场(摘要号：11503)[ ...

In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be ...

Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy. Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction ...

Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC). Obesity paradox in non-small cell lung cancer (NSCLC) patients on immune ...

癌度医学临床招募资讯微信群（点击）肿瘤治疗一个常见的误区是：“用的药越多，治疗肿瘤的效果越好”，但事实并非如此，任何药物都有不良反应，如果不能对症联合药物反而适得其反。最近的LEAP-006临床研究发现，在治疗晚期非小细胞肺癌时，在PD-1联合化疗的 ...

免疫药物搭配化疗的合併疗法成趋势！东洋（4105)26日表示，旗下自制用于非小细胞肺癌的化疗学名药Pemetrexed，获健保署自6月1日起正式将Pembrolizumab併用Pemetrexed的合併疗法纳入给付，将为营运带来新动能。东洋表 ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

Osimertinib (Tagrisso, AstraZeneca) with pemetrexed and platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...